Scarica l'app Stockscreener
87.36
4.63%
-4.72
Precedente Chiudi:
$92.08
Aprire:
$91.57
Volume 24 ore:
105.10K
Relative Volume:
0.45
Capitalizzazione di mercato:
$1.04B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.95%
1M Prestazione:
-12.42%
6M Prestazione:
+128.51%
1 anno Prestazione:
+576.04%
Intervallo 1D:
$86.08
$91.57
Intervallo di 1 settimana:
$86.08
$99.72
Portata 52W:
$12.10
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
87.91 | 1.09B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Mizuho | Outperform |
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Published on: 2026-01-23 00:45:18 - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
FOMO Trade: Does RAIN stock benefit from AI growthQuarterly Profit Report & Short-Term High Return Ideas - baoquankhu1.vn
Palvella’s QTORIN pipeline targets a breakout moment in rare skin care - MSN
Analyst Calls: Is Palvella Therapeutics Inc stock forming a cup and handle2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from BTIG Research - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December - MarketBeat
Palvella’s rare-disease pipeline gains momentum amid positive topline data - S&P Global
Pharma News: Is Palvella Therapeutics Inc a turnaround storyWeekly Investment Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Moving Averages: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aug Action: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aspiriant LLC Acquires Shares of 5,852 Palvella Therapeutics, Inc. $PVLA - Defense World
Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook - TipRanks
Palvella Therapeutics, Inc. Advances Rare Disease Therapies - TradingView — Track All Markets
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics provides corporate update and 2026 outlook - marketscreener.com
Palvella Therapeutics Provides Corporate Update And 2026 Outlook - TradingView — Track All Markets
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies - The Manila Times
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push - MyChesCo
Will Palvella Therapeutics Inc. (PI6) stock benefit from commodity supercycleForecast Cut & Proven Capital Preservation Methods - Улправда
A new gel that could become the first treatment for rare skin diseases - Stock Titan
Will Palvella Therapeutics Inc. stock maintain growth storyMarket Growth Summary & Low Drawdown Investment Ideas - Улправда
Palvella Therapeutics stock maintains Buy rating at TD Cowen ahead of key trial data - Investing.com Canada
Why analysts recommend Palvella Therapeutics Inc. (PI6) stockJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - Улправда
What is the fair value of Palvella Therapeutics Inc. stock now2025 Support & Resistance & Verified Technical Trade Signals - ulpravda.ru
Will Palvella Therapeutics Inc. stock pay special dividendsPortfolio Return Report & Low Risk High Reward Ideas - ulpravda.ru
BTIG Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Mizuho - Defense World
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - MyChesCo
Aug Swings: Will Palvella Therapeutics Inc stock maintain growth storyJuly 2025 Technicals & High Accuracy Buy Signal Tips - moha.gov.vn
Mizuho Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.5%Here's What Happened - MarketBeat
Palvella Therapeutics Appoints Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - citybiz
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - The Manila Times
Palvella Therapeutics Strengthens Leadership Team with - GlobeNewswire
Mizuho initiates coverage on Palvella Therapeutics stock with Outperform rating - Investing.com Canada
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Stock Watch: Biotech Acquisitions Drive Sector Momentum Going Into 2026 - Citeline News & Insights
Earnings Recap: Will Palvella Therapeutics Inc stock pay special dividendsEarnings Recap Report & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Palvella Therapeutics (NASDAQ:PVLA) Trading Down 4.9% – What’s Next? - Defense World
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - MSN
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9%Here's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 3.9% – Still a Buy? - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 3.9%Should You Buy? - MarketBeat
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy? - Defense World
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock enhance shareholder valueSector-Based Investing & Free Proven Portfolio Growth Strategies - Bollywood Helpline
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1%Time to Buy? - MarketBeat
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):